Elzomy 3.5 Mg Powder For Solution For Injection 3.5 mg Powder for solution for injection.
PDF Leaflet Revision Date: 30 November 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and relapsed mantle cell lymphoma.
Dosage (summary)
1.3 mg/mu00b2 twice weekly for 2 weeks, then 10-day rest; adjust for toxicity.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; discontinue breastfeeding during treatment.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Oral hypoglycaemics
Contraindications
- Hypersensitivity to bortezomib
- Severe hepatic impairment
- Acute pulmonary disease
Common side effects
- Nausea
- Diarrhoea
- Constipation
- Fatigue
- Thrombocytopenia
Counselling Points
- Monitor for signs of neuropathy
- Use effective contraception
- Report any severe side effects
Serious warnings
- Risk of PML
- Severe hypotension
- Cardiac failure
- Gastrointestinal toxicity
Important Disclaimer
The Elzomy 3.5 Mg Powder For Solution For Injection 3.5 mg Powder for solution for injection. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
